First Impressions on Healthscope (HSO) Interim Results

Healthscopes divisional EBITDA in hospitals went up 10.4% to $327.6m, EBITDA margin was also up 80bp to 17.7%. International Pathology was up 13.7% to $60m and EBITDA margin up 120bp to 24.7%. Medical Centres up 0.3% to $15m and EBITDA margin up 10bp to 24.7%. Discontinued Australian Pathology business' operating EBITDA was down 33% to $7.5m and EBITDA margin down 110bp to 2.7% . Healthscopes outlook: “FY15 has been a successful year for Healthscope and our revenue strategies, combined with our cost strategies around labour and procurement, will continue to deliver further improvements in FY16. During the second half of FY16 we will also commission some large capital projects (Gold Coast, Knox, National Capital) which will lay the foundation for accelerated growth in FY17 and beyond.” Read our full summary here: (VIEW LINK)